新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » Nature报道 » Nat. Med.:蛋白质Sema4D遏制骨骼形成

Nat. Med.:蛋白质Sema4D遏制骨骼形成

来源:新华网 2011-11-03 13:52

日本研究人员日前发现一种遏制骨骼形成的蛋白质,通过抑制这种蛋白质的功能,研究人员成功地在实验鼠身上实现了骨骼再生。

东京医科齿科大学研究人员报告说,他们在实验中发现,分解骨质的破骨细胞会大量分泌一种与调节免疫机能有关的蛋白质“Sema4D”,这种蛋白质会遏制成骨细胞的产生,进而阻止新骨骼的形成。

研究人员制作出能够与“Sema4D”蛋白质结合从而遏制其发挥作用的抗体,然后注射到患有骨质疏松症的实验鼠体内,结果发现其骨骼成功再生,骨密度也有所提高,而且没有明显的副作用。

研究人员说,这一成果有助于开发出通过促进骨骼形成来治疗骨质疏松症和类风湿性关节炎的新药物。

这一研究成果的相关论文刊登在最新一期英国《自然·医学》杂志网络版上。(生物谷 Bioon.com)

 

Suppression of bone formation by osteoclastic expression of semaphorin 4D

Takako Negishi-Koga,Masahiro Shinohara,Noriko Komatsu,Haruhiko Bito,Tatsuhiko Kodama,Roland H Friedel& Hiroshi Takayanagi

Most of the currently available drugs for osteoporosis inhibit osteoclastic bone resorption; only a few drugs promote osteoblastic bone formation. It is thus becoming increasingly necessary to identify the factors that regulate bone formation. We found that osteoclasts express semaphorin 4D (Sema4D), previously shown to be an axon guidance molecule, which potently inhibits bone formation. The binding of Sema4D to its receptor Plexin-B1 on osteoblasts resulted in the activation of the small GTPase RhoA, which inhibits bone formation by suppressing insulin-like growth factor-1 (IGF-1) signaling and by modulating osteoblast motility. Sema4d−/− mice, Plxnb1−/− mice and mice expressing a dominant-negative RhoA specifically in osteoblasts showed an osteosclerotic phenotype due to augmented bone formation. Notably, Sema4D-specific antibody treatment markedly prevented bone loss in a model of postmenopausal osteoporosis. Thus, Sema4D has emerged as a new therapeutic target for the discovery and development of bone-increasing drugs.

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库